Commentary on Jones et al. (2020): Using indirect estimation methods of drug use prevalence to address racial and ethnic health disparities.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis.The Journal of clinical psychiatry · 2022
   Article
2. Risks and Opportunities to Ensure Equity in the Application of Big Data Research in Public Health.Annual review of public health · 2022
   Review

Corrections and comments

• Comment on
  Estimating the prevalence of problem drug use from drug-related mortality data.2020

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as